Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 2.77B | 4.8% |
| Gross Profit | 2.01B | 5.6% |
| Cost of Revenue | 764M | 2.7% |
| Operating expense | 1.26B | 78.2% |
| Net Income | 1.05B | 129.1% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 22.2B | 10.5% |
| Total Liabilities | 6.61B | 23.4% |
| Total Equity | 15.6B | 5.8% |
| Shares Outstanding | 258M | 0.1% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | 1.37B | 136.5% |
| Cash from investing | -348M | 25% |
| Cash from financing | -388M | 8.1% |
EPS
Financial Highlights for Vertex Pharmaceuticals in Q3 '24
Vertex Pharmaceuticals reported a revenue of 2.77B, which is a 4.8% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 2.01B, marking a 5.6% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 764M, a 2.7% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 1.26B, showing a -78.2% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 1.05B, showing a 129.1% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
It was a positive quarter for Vertex Pharmaceuticals with growth in revenue, gross profit, and net income.
